Complementary and Alternative Therapeutics: Rigorous Research is Needed to Support Claims

Annual Review of Pharmacology and Toxicology

Volumn 43, Issue , 2003, Pages 463-484

  Kinsel, Jane F ^a   Straus, Stephen E ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

CAM; Dietary supplements; Drug development; Natural products

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; CHONDROITIN; CURCUMA LONGA EXTRACT; DIGITALIS; ECHINACEA EXTRACT; EDETIC ACID; EPHEDRINE; GINGER EXTRACT; GINKGO BILOBA EXTRACT; GLUCOSAMINE; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; NATURAL PRODUCT; PHENYLPROPANOLAMINE; PSEUDOEPHEDRINE; SABAL EXTRACT; SELENIUM; TETRACYCLINE;

ALTERNATIVE MEDICINE; BIOAVAILABILITY; BIOEQUIVALENCE; BOSWELLIA; CRANBERRY; DIET SUPPLEMENTATION; DRUG CROSS REACTIVITY; DRUG LEGISLATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GOOD MANUFACTURING PRACTICE; HEALTH CARE ORGANIZATION; HISTORY OF MEDICINE; MARKETING; MEDICAL PRACTICE; PRIORITY JOURNAL; REVIEW; FINANCIAL MANAGEMENT; HUMAN; ORGANIZATION AND MANAGEMENT; STANDARD; UNITED STATES;

BOSWELLIA; CURCUMA; CURCUMA LONGA; DIGITALIS; GINKGO BILOBA; HYPERICUM; HYPERICUM PERFORATUM; SABAL; VACCINIUM MACROCARPON; ZINGIBER OFFICINALE;

COMPLEMENTARY THERAPIES; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); RESEARCH SUPPORT; UNITED STATES;

EID: 0042352218     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.43.100901.135757     Document Type: Review

References (41)

1. Astin JA. 1998. Why patients use alternative medicine: results of a national study. JAMA 279:1548-53
2. Duffy J. 1990. The Sanitarians: A History of Public Health, pp. 193-204. Chicago: Univ. Illinois Press
3. Natl. Vital Stat. Rep. 2002. Table 12. Estimated life expectancy at birth in years, by race and sex: death-registration states, 1900-28, and United States, 1929-99. 50(6):33-34
4. Kessler RC, Davis RB, Foster DF, Van Rompay MI, Walters EE, et al. 2001. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann. Intern. Med. 135:262-68
5. Eisenberg DM, David RB, Ettner SL. 1998. Trends in alternative medicine use in the United States, 1990-1997. JAMA 280:1569-75
6. Jellin JM, Batz F, Flitchens K. 2000. Pharmacist's Letter/Prescriber's Letter Natural Medicines Comprehensive Database, pp. 1114-15. Stockton, CA: Ther. Res. Fac.
7. Jellin JM, Batz F, Hitchens K. 2000. Pharmacist's Letter/Prescriber's Letter Natural Medicines Comprehensive Database, pp. 372-74. Stockton, CA: Ther. Res. Fac.
8. PL No. 57-244, 32 Stat. 328 (The Biologics Control Act of 1902)
9. PL No. 59-384, 34 Stat. 768 (Federal Food and Drugs Act of 1906)
10. PL No. 75-717, 52 Stat. 1040 (Federal Food, Drug, and Cosmetic Act of 1938)
11. PL No. 82-215, 65 Stat. 648 (Durham-Humphrey Amendments of 1951)
12. PL No. 87-781,76 Stat. 780 (Kefauver Harris Amendment of 1962)
13. PL No. 97-414, 96 Stat. 2049 (The Orphan Drug Act of 1983)
14. PL No. 98-417, 98 Stat. 1585 (The Drug Price and Patent Term Restoration Act of 1984)
15. PL No. 103-417, 108 Stat. 4325 (Dietary Supplement Health and Education Act of 1994)
16. Bass IS, Raubicheck CJ. 2000. Marketing Dietary Supplements. Washington, DC: Food and Drug Law Inst.
17. http://www.fda.gov/medwatch/safety/ 2002/safety02.htm
18. Committee on Government Reform. US House of Representatives. 2001. House Government Reform Committee Six Years After the Enactment of DSHEA: The Status of National and International Dietary Supplement Regulation. March 20, 2001
19. Rozema TC. 1997. Protocols for chelation therapy. J. Adv. Med. 10(1): 1-100
20. Enforcement Action Under the New Drug Provisions of the Federal Food, Drug, and Cosmetic Act; Certain OTC Drug Products; Advisory Opinion. 18 Nov. 1983. 48 Fed. Regist. 224:52513-14
21. Engel LW, Straus SE. 2002. Development of therapeutics: opportunities within complementary and alternative medicine. Nat. Rev. 1:229-37
22. Harkey MR, Henderson GL, Gershwin ME, Stem JS, Hackman RM. 2001. Variability in commercial ginseng products: an analysis of 25 preparations. Am. J. Clin. Nutr. 73:1101-6
23. Kontiokari T, Sundqvist K, Nuutinen M, Pokka T, Koskela M, Uhari M. 2001. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ 322:1-5
24. Engel LW, Weinberg MS, Coates PM. 2001. NCCAM-industry colloquium: exploring opportunities for collaboration. J. Altern. Complement. Med. 7(5):579-82
25. http://www.fda.gov/cder/regulatory/applications/anda.htm
26. Stockley IH. 1994. Drug Interactions-A Source Book of Adverse Interactions, Their Mechanisms, Clinical Importance and Management. Oxford: Blackwell Sci.
27. Deleted in proof
28. Brown DJ. 1996. Herbal medicine: an introduction for pharmacists. Part II. Categories of herbal medicine. Natl. Assoc. Represent. Indep. Retail Pharm. 10:127-44
29. Rosenblatt M, Mindel J. 1997. Spontaneous hyphema associated with ingestion of Ginkgo boloba extract. N. Engl. J. Med. 336:1108
30. Eisenberg DM, Kessler RC, Van Romapy MI, Kaptchuk TJ, Wilkey SA, et al. 2001. Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann. Intern. Med. 135:344-51
31. Blumenthal DJ. 2001. Herb sales down 15 percent in mainstream market. Herbal-Gram 51:69
32. Yue Q-Y, Bergquist C, Gerden B. 2000. Safety of St. John's wort (Hypericum perforatum). Lancet 355:576-77
33. Willson TM, Kliewer SA. 2002. PXR, CAR and drug metabolism. Nat. Rev. 1:259-66
34. Brown CH. 2002. Overview of drug interactions modulated by cytochrome P450. US Pharmacist 26(4):HS26-45
35. Piscatelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. 2000. Indinavir concentrations and St. John's wort. Lancet 355(9203):547-48
36. Baede-van Dijk PA. 2000. Drug interactions of Hypericum perforatum (St. John's wort) are potentially hazardous. Ned. Tijdschr. Geneeskd. 144(17):811-12
37. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. 2000. Acute heart transplant rejection due to Saint John's wort. Lancet 355:548-49
38. rd AACR meeting, San Francisco, CA
39. http://www.fda.gov/cder/drug/advisory/stjwort.htm
40. Philipp, M, Kohnen R, Hiller K-O, Linde K, Berner M. 1999. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomized multicentre study of treatment for eight weeks. BMJ 319:1534-39
41. Davidson JRT, Hypericum Depression Trial Study Group. 2002. Effect of Hypericum perforatum (St. John's wort) in major depressive disorder. JAMA 287(14):1807-14